Deregulated E2F-1 blocks terminal differentiation and loss of leukemogenicity of M1 myeloblastic leukemia cells without abrogating induction of p15(INK4B) and p16(INK4A)

Blood

Volumn 96, Issue 2, 2000, Pages 475-482

  Amanullah, Arshad ^b   Hoffman, Barbara ^b   Liebermann, Dan A ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; PROTEIN P15; PROTEIN P16; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; GROWTH DISORDER; LEUKEMOGENESIS; MACROPHAGE; MOUSE; MYELOID LEUKEMIA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0034661508     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.2.475.014k38_475_482     Document Type: Article

References (75)

1. Mudryj M, Hiebert SW, Nevins JR. A role for the adenovirus inducible E2F transcription factor in a proliferation dependent signal transduction pathway. EMBO J. 1990;9:2179.
2. Hiebert SW, Blake M, Azizkhan J, Nevins JR. Role of E2F transcription factor in E1A-mediated trans activation of cellular genes. J Virol. 1991;65: 3547.
3. Dalton S. Cell cycle regulation of the human cdc2 gene. EMBO J. 1992;11:1797.
4. Johnson DG, Schwarz JK, Cress WD, Nevins JR. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature. 1993; 365:349.
5. Slansky JE, Li Y, Kaelin WG, Farnham PJ. A protein synthesis-dependent increase in E2F1 mRNA correlates with growth regulation of the dihydrofolate reductase promoter. Mol Cell Biol. 1993;13:1610.
6. Dou QP, Zhao S, Levin AH, Wang J, Helin K, Pardee AB. G1/S-regulated E2F-containing protein complexes bind to the mouse thymidine kinase gene promoter. J Biol Chem. 1994;269:1306.
7. Ohtani K, DeGregori J, Leone G, Herendeen DR, Kelly TJ, Nevins JR. Expression of the HsOrc1 gene, a human ORC1 homolog, is regulated by cell proliferation via the E2F transcription factor. Mol Cell Biol. 1996;16:6977.
8. Bandara LR, Buck VM, Zamanian M, Johnston LH, La Thangue NB. Functional synergy between DP-1 and E2F-1 in the cell cycle-regulating transcription factor DRTF1/E2F EMBO J. 1993;12: 4317.
9. Helin K, Wu CL, Fattaey AR, et al. Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation. Genes Dev. 1993;7:1850.
10. Huber HE, Edwards G, Goodhart PJ, et al. Transcription factor E2F binds DNA as a heterodimer. Proc Natl Acad Sci USA. 1993;90:3525.
11. Krek W, Livingston DM, Shirodkar S. Binding to DNA and the retinoblastoma gene product promoted by complex formation of different E2F family members. Science. 1993;262:1557.
12. La Thangue NB. DP and E2F proteins: components of a heterodimeric transcription factor implicated in cell cycle control. Curr Opin Cell Biol. 1994;6:443.
13. Wu CL, Zukerberg LR, Ngwu C, Harlow E, Lees JA. In vivo association of E2F and DP family proteins. Mol Cell Biol. 1995;15:2536.
14. Zhang Y, Chellappan SP. Cloning and characterization of human DP2, a novel dimerization partner of E2F. Oncogene. 1995;10:2085.
15. Hiebert SW, Chellappan SP, Horowitz JM, Nevins JR. The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. Genes Dev. 1992;6:177.
16. Helin K, Harlow E, Fattaey A. Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein. Mol Cell Biol. 1993;13:6501.
17. Claudio PP, Howard CM, Baldi A. et al. p130/ pRb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p107. Cancer Res. 1994;54:5556.
18. Smith EJ, Nevins JR.The Rb-related p107 protein can suppress E2F function independently of binding to cyclin A/cdk2. Mol Cell Biol. 1995;15: 338.
19. Vairo G, Livingston DM, Ginsberg D. Functional interaction between E2F-4 and p130: evidence for distinct mechanisms underlying growth suppression by different retinoblastoma protein family members. Genes Dev. 1995;9:869.
20. Qin XQ, Livingston DM, Ewen M, Sellers WR, Arany Z, Kaelin WG Jr. The transcription factor E2F-1 is a downstream target of RB action. Mol Cell Biol. 1995;15:742.
21. Flemington EK, Speck SH, Kaelin WG Jr. E2F-1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product. Proc Natl Acad Sci U S A. 1993;90: 6914.
22. Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev. 1993;7:331.
23. Beijersbergen RL, Carlee L, Kerkhoven RM, Bernards R. Regulation of the retinoblastoma protein-related p107 by G1 cyclin complexes. Genes Dev. 1995;9:1340.
24. Suzuki-Takahashi I, Kitagawa M, Saijo M, et al. The interactions of E2F with pRB and with p107 are regulated via the phosphorylation of pRB and p107 by a cyclin-dependent kinase. Oncogene. 1995;10:1691.
25. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol. 1998;18:753.
26. Peter M, Herskowitz I. Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell. 1994;79:181.
27. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995; 9:1149.
28. Hunter T, Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell. 1994;79: 573.
29. Dobrowolski SF, Stacey DW, Harter ML, Stine JT, Hiebert SW. An E2F dominant negative mutant blocks E1A induced cell cycle progression. Oncogene. 1994;9:2605.
30. Shan B, Lee WH. Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol Cell Biol. 1994;14:8166.
31. Qin XQ, Livingston DM, Kaelin WG Jr, Adams PD. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci U S A. 1994; 91:10918.
32. Duronio RJ, O'Farrell PH, Xie JE, Brook A, Dyson N. The transcription factor E2F is required for S phase during Drosophila embryogenesis. Genes Dev. 1995;9:1445.
33. INK4A-mediated growth suppression. Mol Cell Biol. 1996;16:1047.
34. Wu X, Levine AJ. p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci U S A. 1994;91:3602.
35. Hiebert SW, Packham G, Strom DK, et al. E2F-1: DP-1 induces p53 and overrides survival factors to trigger apoptosis. Mol Cell Biol. 1995;15:6864.
36. Kowalik TF, DeGregori J, Schwarz JK, Nevins JR. E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. J Virol. 1995;69:2491.
37. Guy CT, Zhou W, Kaufman S, Robinson MO. E2F-1 blocks terminal differentiation and causes proliferation in transgenic megakaryocytes. Mol Cell Biol. 1996;16:685.
38. Strom DK, Cleveland JL, Chellappan S, Nip J, Hiebert SW. E2F-1 and E2F-3 are functionally distinct in their ability to promote myeloid cell cycle progression and block granulocyte differentiation. Cell Growth Differ. 1998;9:59.
39. Liebermann DA, Hoffman B. Differentiation primary response genes and proto-oncogenes as positive and negative regulators of terminal hematopoietic cell differentiation. Stem Cells (Dayt). 1994;12:352.
40. Liebermann DA, Hoffman B, Steinman RA. Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene. 1995;11:199.
41. Ichikawa Y. Differentiation of a call line of myeloid leukemia. J Cell Physiol. 1969;74:223.
42. Lord KA, Abdollahi A, Hoffman-Liebermann B, Liebermann DA. Dissection of the immediate early response of myeloid leukemia cells to terminal differentiation and growth inhibitory stimuli. Cell Growth Differ. 1990;1:637.
43. Hoffman-Liebermann B, Liebermann DA. Interleukin-6-and leukemia inhibitory factor-induced terminal differentiation of myeloid leukemia cells is blocked at an intermediate stage by constitutive c-myc. Mol Cell Biol. 1991;11:2375.
44. Lord KA, Abdollahi A, Thomas SM, et al. Leukemia inhibitory factor and interleukin-6 trigger the same immediate early response, including tyrosine phosphorylation, upon induction of myeloid leukemia differentiation. Mol Cell Biol. 1991;11: 4371.
45. Selvakumaran M, Liebermann DA, Hoffman-Liebermann B: Deregulated c-myb disrupts interleukin-6-or leukemia inhibitory factor-induced myeloid differentiation prior to c-myc: role in leukemogenesis. Mol Cell Biol. 1992;12:2493.
46. Hoffman-Liebermann B, Liebermann DA. Suppression of c-myc and c-myb is tightly linked to terminal diferentiation induced by IL6 or LIF and not growth inhibition in myeloid leukemia cells. Oncogene. 1991;6:903.
47. Hawley RG. High-titer retroviral vectors for efficient transduction of functional genes into murine hematopoietic stem cells. Ann N Y Acad Sci. 1994;716:327.
48. Lord KA, Abdollahi A, Hoffman-Liebermann B, Liebermann DA. Proto-oncogenes of the fos/jun family of transcription factors are positive regulators of myeloid differentiation. Mol Cell Biol. 1993; 13:841.
49. Krishnaraju K, Nguyen HQ, Liebermann DA, Hoffman B. The zinc finger transcription factor Egr-1 potentiates macrophage differentiation of hematopoietic cells. Mol Cell Biol. 1995;15:5499.
50. Hibshoosh H, Johnson M, Weinstein IB. Effects of overexpression of omithine decarboxylase (ODC) on growth control and oncogene-induced cell transformation. Oncogene. 1991;6:739.
51. Selvakumaran M, Liebermann DA, Hoffman B. The proto-oncogene c-myc blocks myeloid differentiation independently of its target gene ornithine decarboxylase. Blood. 1996;88:1248.
52. Ausubel FM, Brent R, Kingston RE, et al. Current Protocols in Molecular Biology. New York, NY: Greene & Wiley-Interscience; 1992.
53. Hsieh JK, Fredersdorf S, KouzaridesT, Martin K, Lu X. E2F1-induced apoptosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction. Genes Dev. 1997;11:1840.
54. Hunt KK, DengJ, Liu TJ, et al. Adenovirus-mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53. Cancer Res. 1997;57:4722.
55. Nip J, Strom DK, Fee BE, Zambetti G, Cleveland JL, Hiebert SW. E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis. Mol Cell Biol. 1997;17:1049.
56. Phillips AC, Bates S, Ryan KM, Helin K, Vousden KH. Induction of DNA synthesis and apoptosis are separable functions of E2F-1. Genes Dev. 1997;11:1853.
57. Lord KA, Hoffman-Liebermann B, Liebermann DA. Complexity of the immediate early response of myeloid cells to terminal differentiation and growth arrest includes ICAM-1, Jun-B and histone variants. Oncogens. 1990;5:387.
58. Abdollahi A, Lord KA, Hoffman-Liebermann B, Liebermann DA. Interferon regulatory factor 1 is a myeloid differentiation primary response gene induced by interleukin 6 and leukemia inhibitory factor: role in growth inhibition. Cell Growth Differ. 1991;2:401.
59. Lotem J, Sachs L. In vivo induction of normal differentiation in myeloid leukemia cells. Proc Natl Acad Sci U S A. 1978;75:3781.
60. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature. 1991;352:345.
61. Selvakumaran M, Lin HK, Miyashita T, et al. Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways. Oncogene. 1994;9:1791.
62. Wang J, Helin K, Jin P, Nadal-Ginard B. Inhibition of in vitro myogenic differentiation by cellular transcription factor E2F1. Cell Growth Differ. 1995;6: 1299.
63. Steinman RA, Huang J, Yaroslavskiy B, Goff JP, Ball ED, Nguyen A. Regulation of p21 (WAF1) expression during normal myeloid differentiation. Blood. 1998;91:4531.
64. Muto A, Kizaki M, Yamato K, et al. 1,25-Dihydroxyvitamin D3 induces differentiation of a retinoic acid-resistant acute promyelocytic leukemia cell line (UF-1) associated with expression of p21(WAF1/CIP1) and p27(KIP1). Blood. 1999;93: 2225.
65. Alevizopoulos K, Vlach J, Hennecke S, Amati B. Cyclin E and c-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins. EMBO J. 1997;16:5322.
66. Lukas J, Herzinger T, Hansen K, et al. Cyclin E-induced S phase without activation of the pRb/ E2F pathway. Genes Dev. 1997;11:1479.
67. Leng X, Connell-Crowley L, Goodrich D, Harper JW. S-Phase entry upon ectopic expression of G1 cyclin-dependent kinases in the absence of retinoblastoma protein phosphorylation. Curr Biol. 1997;7:709.
68. Johnson DG, Cress WD, Jakoi L, Nevins JR. Oncogenic capacity of the E2F1 gene. Proc Natl Acad Sci U S A. 1994;91:12823.
69. Singh P, Wong SH, Hong W. Overexpression of E2F-1 in rat embryo fibroblasts leads to neoplastic transformation. EMBO J. 1994;13:3329.
70. Xu G, Livingston DM, Krek W. Multiple members of the E2F transcription factor family are the products of oncogenes. Proc Natl Acad Sci U S A. 1995;92:1357.
71. Field SJ, Tsai FY, Kuo F, et al. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell. 1996;85:549.
72. Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, Dyson NJ. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell. 1996;85:537.
73. Pierce AM, Fisher SM, Conti CJ, Johnson DG. Deregulated expression of E2F1 induces hyperplasia and cooperates with ras in skin tumor development. Oncogene. 1998;16:1267.
74. Guillouf C, Grana X, Selvakumaran M, et al. Dissection of the genetic programs of p53-mediated G1 growth arrest and apoptosis: blocking p53-induced apoptosis unmasks G1 arrest. Blood. 1995;85:2691.
75. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81:323.